DE2366498C2 - - Google Patents

Info

Publication number: DE2366498C2
Authority: DE; Germany
Prior art keywords: vitamin; antirachitic; compounds; doses; hydroxycholecalciferol
Prior art date: 1972-06-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

DE19732366498

Other languages

German (de)

English (en)

Other versions

DE2366498A1 (fr

Inventor

Marion David Cincinnati Ohio Us Francis

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Procter and Gamble Co

Original Assignee

Procter and Gamble Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1972-06-08

Filing date

1973-06-02

Publication date

1987-08-20

1973-06-02 Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co

1982-09-23 Publication of DE2366498A1 publication Critical patent/DE2366498A1/de

1987-08-20 Application granted granted Critical

1987-08-20 Publication of DE2366498C2 publication Critical patent/DE2366498C2/de

Status Expired legal-status Critical Current

Links

150000001875 compounds Chemical class 0.000 claims description 15
230000001749 antrachitic effect Effects 0.000 claims description 12
DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims description 9
229940088594 vitamin Drugs 0.000 claims description 8
229930003231 vitamin Natural products 0.000 claims description 8
235000013343 vitamin Nutrition 0.000 claims description 8
239000011782 vitamin Substances 0.000 claims description 8
150000003839 salts Chemical class 0.000 claims description 7
MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims description 7
MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims description 6
239000003795 chemical substances by application Substances 0.000 claims description 6
229960002061 ergocalciferol Drugs 0.000 claims description 6
235000001892 vitamin D2 Nutrition 0.000 claims description 6
239000011653 vitamin D2 Substances 0.000 claims description 6
150000003722 vitamin derivatives Chemical class 0.000 claims description 6
OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 claims description 3
229960002535 alfacalcidol Drugs 0.000 claims description 3
GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims description 3
238000007910 systemic administration Methods 0.000 claims description 3
LAEKPCQYMVJVAK-PBWGLAFFSA-N (1s,3e,4s)-3-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1/C[C@@H](O)CC[C@@H]1C LAEKPCQYMVJVAK-PBWGLAFFSA-N 0.000 claims description 2
JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 claims description 2
239000003872 25-hydroxy-cholecalciferol Substances 0.000 claims description 2
JWUBBDSIWDLEOM-ZMHTYULMSA-N 5,6-trans-25-hydroxyvitamin D3 Chemical compound C([C@@H]([C@]1(CCC2)C)[C@@H](CCCC(C)(C)O)C)CC1\C2=C/C=C1\C[C@H](O)CCC1=C JWUBBDSIWDLEOM-ZMHTYULMSA-N 0.000 claims description 2
235000021318 Calcifediol Nutrition 0.000 claims description 2
JWUBBDSIWDLEOM-DTOXIADCSA-N calcidiol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DTOXIADCSA-N 0.000 claims description 2
QYSXJUFSXHHAJI-FVUVGDFOSA-N 5,6-trans-vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1/C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-FVUVGDFOSA-N 0.000 claims 1
210000000988 bone and bone Anatomy 0.000 description 10
201000010099 disease Diseases 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
238000011282 treatment Methods 0.000 description 7
208000001132 Osteoporosis Diseases 0.000 description 6
230000033558 biomineral tissue development Effects 0.000 description 6
230000000694 effects Effects 0.000 description 6
QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 5
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
208000010191 Osteitis Deformans Diseases 0.000 description 4
229910019142 PO4 Inorganic materials 0.000 description 4
230000002159 abnormal effect Effects 0.000 description 4
230000037396 body weight Effects 0.000 description 4
229910052791 calcium Inorganic materials 0.000 description 4
239000011575 calcium Substances 0.000 description 4
238000000034 method Methods 0.000 description 4
239000000203 mixture Substances 0.000 description 4
230000001575 pathological effect Effects 0.000 description 4
235000021317 phosphate Nutrition 0.000 description 4
235000005282 vitamin D3 Nutrition 0.000 description 4
239000011647 vitamin D3 Substances 0.000 description 4
229940021056 vitamin d3 Drugs 0.000 description 4
206010065687 Bone loss Diseases 0.000 description 3
208000027868 Paget disease Diseases 0.000 description 3
239000001506 calcium phosphate Substances 0.000 description 3
235000011010 calcium phosphates Nutrition 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
208000027202 mammary Paget disease Diseases 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
238000005303 weighing Methods 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
102000055006 Calcitonin Human genes 0.000 description 2
108060001064 Calcitonin Proteins 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 2
150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000011591 potassium Substances 0.000 description 2
239000002243 precursor Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
210000002303 tibia Anatomy 0.000 description 2
OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
206010070817 Bone decalcification Diseases 0.000 description 1
UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 description 1
KMHZPJNVPCAUMN-UHFFFAOYSA-N Erbon Chemical compound CC(Cl)(Cl)C(=O)OCCOC1=CC(Cl)=C(Cl)C=C1Cl KMHZPJNVPCAUMN-UHFFFAOYSA-N 0.000 description 1
DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010031285 Osteoporosis postmenopausal Diseases 0.000 description 1
229910018828 PO3H2 Inorganic materials 0.000 description 1
208000027067 Paget disease of bone Diseases 0.000 description 1
208000037273 Pathologic Processes Diseases 0.000 description 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
206010070863 Toxicity to various agents Diseases 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
229930003316 Vitamin D Natural products 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
WXQWKYFPCLREEY-UHFFFAOYSA-N azane;ethanol Chemical class N.CCO.CCO.CCO WXQWKYFPCLREEY-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
208000016738 bone Paget disease Diseases 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
235000020964 calcitriol Nutrition 0.000 description 1
239000011612 calcitriol Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
238000005115 demineralization Methods 0.000 description 1
230000002328 demineralizing effect Effects 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
235000020930 dietary requirements Nutrition 0.000 description 1
-1 disodium dihydrogen salt Chemical class 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
GWBBVOVXJZATQQ-UHFFFAOYSA-L etidronate disodium Chemical compound [Na+].[Na+].OP(=O)([O-])C(O)(C)P(O)([O-])=O GWBBVOVXJZATQQ-UHFFFAOYSA-L 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
150000004673 fluoride salts Chemical class 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
150000002680 magnesium Chemical class 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000002969 morbid Effects 0.000 description 1
230000017066 negative regulation of growth Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
230000009054 pathological process Effects 0.000 description 1
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
239000011833 salt mixture Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
IUTCEZPPWBHGIX-UHFFFAOYSA-N tin(2+) Chemical compound [Sn+2] IUTCEZPPWBHGIX-UHFFFAOYSA-N 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
235000019166 vitamin D Nutrition 0.000 description 1
239000011710 vitamin D Substances 0.000 description 1
150000003710 vitamin D derivatives Chemical class 0.000 description 1
229940046008 vitamin d Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3839—Polyphosphonic acids

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DE19732366498 1972-06-08 1973-06-02 Expired DE2366498C2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US26093972A	1972-06-08	1972-06-08
US36135473A	1973-05-17	1973-05-17

Publications (2)

Publication Number	Publication Date
DE2366498A1 DE2366498A1 (fr)	1982-09-23
DE2366498C2 true DE2366498C2 (fr)	1987-08-20

Family

ID=26948280

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DE19732328234 Expired DE2328234C2 (de)	1972-06-08	1973-06-02	Zur systemischen Verabreichung geeignetes Mittel zur Inhibierung der Mobilisierung von Calciumphosphat
DE19732366498 Expired DE2366498C2 (fr)	1972-06-08	1973-06-02

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DE19732328234 Expired DE2328234C2 (de)	1972-06-08	1973-06-02	Zur systemischen Verabreichung geeignetes Mittel zur Inhibierung der Mobilisierung von Calciumphosphat

Country Status (8)

Country	Link
AU (1)	AU474216B2 (fr)
CA (1)	CA1007987A (fr)
DE (2)	DE2328234C2 (fr)
FR (1)	FR2187292B1 (fr)
GB (1)	GB1401548A (fr)
IE (1)	IE37774B1 (fr)
NL (1)	NL176747C (fr)
PH (1)	PH9853A (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2553962A1 (de) *	1975-12-01	1977-06-08	Henkel & Cie Gmbh	Pharmazeutische praeparate zur behandlung von stoerungen des calciumstoffwechsels
DE2553963A1 (de) *	1975-12-01	1977-06-08	Henkel & Cie Gmbh	Pharmazeutische praeparate zur behandlung von stoerungen des calciumstoffwechsels
JPS603045B2 (ja) *	1976-04-19	1985-01-25	中外製薬株式会社	１α―ヒドロキシビタミンＤ類軟カプセルの製造方法
AU2649977A (en) *	1976-07-15	1979-01-04	Procter & Gamble	Pharmaceutical composition
DE3147189A1 (de) *	1981-11-27	1983-06-01	Siemens AG, 1000 Berlin und 8000 München	Zugentlastung fuer ein innerhalb eines pruefsteckers zu haltendes kabel
IT1201087B (it) *	1982-04-15	1989-01-27	Gentili Ist Spa	Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
DE3540150A1 (de) *	1985-11-13	1987-05-14	Boehringer Mannheim Gmbh	Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PH9776A (en) *	1967-12-11	1976-03-17	M Francis	Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue and method of use
PH9573A (en) *	1968-03-04	1976-01-16	M Francis	Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue and method of use thereof
US3584125A (en) *	1968-12-23	1971-06-08	Procter & Gamble	Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue

1973
- 1973-06-01 PH PH14686A patent/PH9853A/en unknown
- 1973-06-02 DE DE19732328234 patent/DE2328234C2/de not_active Expired
- 1973-06-02 DE DE19732366498 patent/DE2366498C2/de not_active Expired
- 1973-06-07 AU AU56624/73A patent/AU474216B2/en not_active Expired
- 1973-06-07 FR FR7320810A patent/FR2187292B1/fr not_active Expired
- 1973-06-07 CA CA173,483A patent/CA1007987A/en not_active Expired
- 1973-06-08 IE IE93573A patent/IE37774B1/xx unknown
- 1973-06-08 GB GB2745773A patent/GB1401548A/en not_active Expired
- 1973-06-08 NL NL7308017A patent/NL176747C/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE2366498A1 (fr)	1982-09-23
PH9853A (en)	1976-04-13
FR2187292A1 (fr)	1974-01-18
DE2328234C2 (de)	1983-03-10
CA1007987A (en)	1977-04-05
AU5662473A (en)	1974-12-12
NL176747C (nl)	1985-06-03
DE2328234A1 (de)	1974-01-03
NL176747B (nl)	1985-01-02
IE37774L (en)	1973-12-08
GB1401548A (en)	1975-07-16
FR2187292B1 (fr)	1976-12-31
NL7308017A (fr)	1973-12-11
IE37774B1 (en)	1977-10-12
AU474216B2 (en)	1976-07-15

Legal Events

Date	Code	Title	Description
1982-09-23	Q172	Divided out of (supplement):	Ref country code: DE Ref document number: 2328234
1982-12-16	8110	Request for examination paragraph 44
1987-08-20	AC	Divided out of	Ref country code: DE Ref document number: 2328234 Format of ref document f/p: P
1987-08-20	D2	Grant after examination
1988-02-25	8364	No opposition during term of opposition
1991-06-06	8339	Ceased/non-payment of the annual fee

Publication	Publication Date	Title
DE69634357T2 (de)	2006-01-12	Formulierungen mit dem wasserfreien mononatriumsalz von alendronat und deren verwendung zur behandlung von knochenkrankheiten
DE69629184T2 (de)	2004-05-06	Verwendung von vitamin d2 oder vitamin d4-derivaten zur herstellung eines medikamentes zur behandlung des sekundären hyperparathyroidismus
DE2405254C2 (de)	1982-05-27	Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
DE60113537T3 (de)	2013-05-29	Methode zur verabreichung von biphosphonaten
DE69726879T2 (de)	2004-10-14	Biphosphonat-formulierung mit brausewirkung
DE2534034A1 (de)	1976-02-12	Mundpflegemittel
Bonjour et al.	1975	Action of 1, 25-dihydroxyvitamin D3 and a diphosphonate on calcium metabolism in rats
DE3201865C2 (de)	1986-12-11	Verwendung von 6-Amino-1-hydroxyhexan-1,1- diphosphonsäure und Derivaten davon zur Behandlung der Osteopathie
DE2366498C2 (fr)	1987-08-20
DE1813659C3 (de)	1974-11-14	Arzneimittel zur Verhinderung der anomalen Mobilisierung und Ablagerung von Calciumphosphat in menschlichen und tierischen Geweben
EP0037488B1 (fr)	1984-09-19	Composition pharmaceutique pour la guérison des affections inflammatoires et/ou dégénératives et/ou atrophiées des membranes muqueuses
DE3033545A1 (de)	1981-04-02	Verwendung bekannter antiallergener mittel bei der bekaempfung von pathologischen mineralresorptionszustaenden
DE69534923T2 (de)	2006-11-23	Anabolische zubereitung für knochenmasse enthaltend olpadronat
DE2606533A1 (de)	1976-08-26	Therapeutisches mittel
DE2226273C2 (de)	1982-12-30	Präparate zur Behandlung der Osteoporose
DE1910489C3 (de)	1978-03-02	Arzneimittel zum Hemmen anomaler Calciumphosphatablagerung und -mobilisierung in Geweben
DE1667903C3 (de)	1982-02-18	Verwendung von Cysteinderivaten zur Herstellung von per oral verabreichbaren Mitteln zur Bekämpfung der Seborrhoe
EP0086476B1 (fr)	1986-05-07	Utilisation de dérivés du cholécalciférol
DE1916010A1 (de)	1969-10-09	Pharmazeutische Zusammensetzung aus einem Corticosteroid und einer nicht toxischen,assimilierbaren phosphathaltigen Substanz
DE3514583A1 (de)	1985-10-31	Verwendung eines zwei- oder mehrphasenmittels zur behandlung oder verhinderung von osteoporose
EP0094644B1 (fr)	1986-07-30	Utilisation d'un dérivé du cholécalciférol
DE2814298A1 (de)	1978-10-05	Bis-(carboxyalkoxy)-butandisaeureverbindungen in oralen zubereitungen zur zahnsteinhemmung
EP0673913B1 (fr)	1999-02-10	Sels de citrates de calcium et d'alcalins ainsi que leur utilisation comme médicaments
DE2953014A1 (en)	1981-01-08	Osteoplastic promotor
DE1916010C (de)	1971-12-09	Intern zu verabreichendes Arzneimittel auf der Basis von antiphlogistischen Cor ticosteroiden und einer nicht toxischen, assimilierbaren phosphorhaltigen Substanz